China Out-Licensing Heats Up: J&J Inks Deal With Ascletis On HIV Candidate
This article was originally published in PharmAsia News
Executive Summary
In its second deal this month, China-U.S. hybrid Ascletis Inc. has licensed exclusive rights to develop and commercialize a second-generation HIV protease inhibitor in Greater China from Johnson & Johnson.